ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag disease medicine biobusiness pharma regulation

The Growth of Iowa Biotech
Jenny Rood | Aug 1, 2016 | 7 min read
The state’s industry draws inspiration from medicine as well as agriculture.
Pharma Looks to Inflammasome Inhibitors as All-Around Therapies
Rachael Moeller Gorman | Apr 1, 2021 | 10+ min read
Many major biopharmaceutical companies are developing or acquiring drugs that target the NLRP3 inflammasome, a large intracellular complex that researchers say can spark inflammation and stoke diseases of lifestyle and aging.
Pharma’s Ghost Labs Find New Life
Katarina Zimmer | Nov 1, 2019 | 9 min read
Finding new tenants for former drug development sites isn’t always easy. But a new, thriving industry has materialized to do just that.
Biopharma Looks to the Netherlands as European Hub
Jef Akst | Feb 1, 2021 | 7 min read
The recent move of the European Medicines Agency from London to Amsterdam is a reflection of the city’s vibrant life sciences and health sector and supporting industries.
small-molecule therapeutics treat cancer and other diseases
Scientists Take Aim at Disease-Causing RNAs Using Small-Molecule Drugs
Claire Asher | Apr 1, 2019 | 9 min read
Renewed interest from the biotech industry sparks hope for drugging the nucleic acid to treat cancer and other conditions.
Accessing Drugs for Medical Aid-in-Dying
Catherine Offord | Aug 16, 2017 | 9 min read
A fraught market for the barbiturates prescribed to terminally ill patients who choose to end their lives has physicians turning to options outside big pharma.
Early Detection of Dementia with Smart Devices
Rachael Moeller Gorman | May 1, 2020 | 10+ min read
Digital biomarkers of cognitive decline could alert us to the early stages of dementia before irreversible damage occurs.
Natural Killer Cell Therapies Catch Up to CAR T
Bianca Nogrady | Apr 1, 2020 | 8 min read
There’s a new cell-based cancer immunotherapy on the block.
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
Vicki Brower | Apr 1, 2018 | 9 min read
With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.
Researchers in George Church&rsquo;s lab modified wild type ADK proteins (left) in <em >E.coli</em>, furnishing them with an nonstandard amino acid (nsAA) meant to biocontain the resulting bacterial strain.
A Pioneer of The Multiplex Frontier
Rashmi Shivni, Drug Discovery News | May 20, 2023 | 10 min read
George Church is at it again, this time using multiplex gene editing to create virus-proof cells, improve organ transplant success, and protect elephants.

Run a Search

ADVERTISEMENT